Related by context. All words. (Click for frequent words.) 75 perioperative mortality 71 CR nPR 71 MACCE 71 ALT elevation 71 Ishak fibrosis score 70 PASI scores 70 binary restenosis 70 EDSS scores 69 arterial thromboembolic events 69 postintervention 69 nondiabetic patients 69 XIENCE V demonstrated 69 % CI #.#-#.# [003] 69 ischemia driven 68 hip BMD 68 % Confidence Interval 68 events MACE 68 XIENCE V PROMUS Stent 68 CI #.#-#.# [001] 68 TAXUS p value 68 definite stent thrombosis 68 underwent resection 68 p = NS 67 diameter stenosis 67 oxycodone CR 67 underwent CABG 67 placebo dexamethasone 67 HbA1C levels 67 reinfarction 67 primary patency 67 postoperative morbidity 67 postoperative mortality 67 morphometric vertebral fractures 67 biochemical recurrence 67 inhospital mortality 67 pT3 67 radical nephrectomy 67 periprocedural 67 Median PFS 66 angiographic restenosis 66 TAVR 66 CABG surgeries 66 nonfatal MI 66 Stent thrombosis 66 pCR 66 mg BID dose 66 elevated LDH 66 preintervention 66 HbA 1c levels 66 mL/min/#.# m 2 66 hepatectomy 66 biochemical relapse 66 plus dexamethasone 66 lumbar spine BMD 66 coronary revascularization 66 nodal metastases 66 CABG p = 66 MMSE score 66 PSADT 66 NNT = 66 Kaplan Meier analysis 65 prespecified secondary 65 PDP MLR 65 mean baseline A1C 65 achieved ACR# 65 Free Survival PFS 65 QTcF 65 nonsignificant difference 65 KRAS mutations occur 65 EDSS score 65 repeat revascularization 65 RYGB 65 posttreatment 65 relapsed MM 65 BMS p = 65 DAS# remission 65 colectomy 65 Index CDAI 65 % CI #.#-#.# [007] 65 echocardiographic parameters 65 p = .# [001] 65 NIHSS 65 low dose Iluvien 65 SUVmax 65 Complication rates 65 underwent surgical resection 65 adjunctive placebo 65 neuropathy sensory 65 thrombosis embolism 65 mediastinitis 65 % CI #.#-#.# [005] 65 unstable angina pectoris 65 unfractionated heparin UFH 65 & s2 = 65 baseline HbA1c 65 resuscitated cardiac arrest 65 Angiographic 65 postoperative complication 65 microbiological eradication 65 subtrochanteric 64 PREZISTA r arm 64 Adjusted EBITDAR margin 64 stage IIIb IV 64 hepatic resection 64 CCyR 64 mcg albinterferon alfa 2b 64 femoral neck BMD 64 HBeAg seroconversion 64 Infusion Reactions Severe 64 systemic embolism 64 esophagectomy 64 TKAs 64 revascularization procedures 64 death reinfarction 64 locoregional recurrence 64 plus aztreonam 64 CYPHER Stent 64 postoperative chemotherapy 64 ipsilateral stroke 64 lopinavir r arm 64 radical prostatectomy RP 64 confidence interval #.#-#.# 64 angiographic outcomes 64 SLNB 64 Crohn Disease Activity 64 Drug eluting stent 64 PLX STROKE targeting 64 oral diclofenac 64 rectal tenesmus 64 lymphocytosis 64 hemoglobin A1c levels 64 symptomatic intracranial hemorrhage 64 nadroparin 64 tapentadol ER 64 symptomatic VTE 64 pancreatic resection 64 receiving VICTRELIS 64 laparoscopically assisted 64 generalized edema 64 certolizumab 64 revascularized 64 NIHSS score 64 Hb A1C 64 -#.# log# 64 advanced adenoma 64 8mg/kg 64 transurethral resection 64 XIENCE V vs. 64 LV dysfunction 64 malignant neoplasm 64 acute cholecystitis 64 mmHg diastolic 64 MMSE scores 64 achieved CCyR 64 Postoperative 63 lamivudine monotherapy 63 adjunctive ABILIFY 63 TEAEs 63 Coronary Artery Bypass Graft 63 confirmed CCyR 63 VAD implantation 63 Coronary artery bypass graft 63 Kaplan Meier estimates 63 mm Stent 63 PSA nadir 63 NMIBC 63 OPCAB 63 nodular partial response 63 HBeAg negative patients 63 glycated hemoglobin levels 63 REMICADE monotherapy 63 nonfatal myocardial infarction 63 CHD mortality 63 P = .# 63 serum clusterin levels 63 revascularization procedure 63 target lesion revascularization 63 R0 resection 63 recurrent VTE 63 HAM D# scores 63 highly emetogenic 63 IOP lowering 63 reoperations 63 TAXUS Express Stent 63 carotid stenosis 63 oral allopurinol 63 mso footer margin 63 adenoma detection 63 #.#/#.# mmHg [001] 63 Postoperative complications 63 coronary artery bypass grafts 63 Hazard Ratio 63 coronary stenosis 63 radical retropubic prostatectomy 63 MADRS score 63 Y BOCS 63 Radical prostatectomy 63 undetectable HBV DNA 63 LV ejection fraction 63 infliximab monotherapy 63 LAGB 63 deep venous thromboses 63 symptomatic carotid stenosis 63 #.#ng/ml 63 baseline FEV 63 revascularizations 63 Ejection Fraction 63 receiving Vectibix monotherapy 63 preoperative PSA 63 vaginal hysterectomy 63 lymphadenectomy 62 TURBT 62 conjunctival hyperemia 62 Folfox 62 Cypher Stent 62 wedge resection 62 coronary angiograms 62 p ≤ 62 NSTEMI 62 CVD mortality 62 patients undergoing CABG 62 LVEF 62 Febrile neutropenia 62 Case persistency 62 left ventricular systolic 62 rebleeding 62 mL sec 62 atheroma volume 62 interquartile range 62 FluCAM arm 62 Fasting blood glucose 62 primary percutaneous coronary 62 baseline serum creatinine 62 knee arthroplasty 62 prospectively stratified 62 Taxus Stent 62 serum urate 62 joint arthroplasty 62 squamous histology 62 oncologic outcomes 62 perioperative complications 62 lipid lowering agents 62 Flu Cy 62 Currency translation negatively impacted 62 nonoperative 62 everolimus eluting stents 62 #mg BID [001] 62 prednisone prednisolone plus 62 5-FU/LV 62 ejection fractions 62 probable stent thrombosis 62 CI -#.# 62 radial artery grafts 62 sirolimus stent 62 % CI #.#-#.# [006] 62 % CI #.#-#.# [008] 62 liver resection 62 CIMZIA ™ 62 Rate ORR 62 ICD implants 62 femoral shaft fracture 62 Thal Dex 62 femoral neck fracture 62 mcg QD 62 colon resection 62 nephron sparing surgery 62 drotrecogin alfa activated 62 chemoradiation therapy 62 pulmonary dysfunction 62 Baseline characteristics 62 cerebrovascular events 62 non valvular atrial 62 ARCOXIA 62 biopsy Gleason 62 oral Hycamtin 62 hip resurfacing arthroplasty 62 DAS# CRP 62 confidence intervals CIs 62 paroxysmal AF 62 nonvertebral 62 ischemic lesions 62 moderate renal impairment 62 TAXUS Liberte Long 62 FHLB borrowings decreased 62 FluCAM 62 asymptomatic carotid stenosis 62 mIU ml 62 hemoglobin A1c HbA1c 62 TURP 62 cEVR 62 MCyR 62 HOMA IR 62 ACR# ACR# 62 total knee arthroplasties 62 affective psychosis 62 reinterventions 62 nonobese patients 62 binary restenosis rate 62 reintervention 62 NYHA functional class 61 Target Lesion Revascularization TLR 61 Index CDAI score 61 lung esophageal 61 psychiatric comorbidities 61 median survivals 61 severe exacerbations 61 mcg kg REBETOL 61 extracapsular extension 61 Nonresidential structures 61 Arch Intern Med 61 Prepaid churn 61 CI #.#-#.# [002] 61 preoperative chemotherapy 61 thoracoscopic lobectomy 61 T2 lesions 61 bivalirudin monotherapy 61 cardiovascular hospitalizations 61 angioplasties stents 61 hepatorenal syndrome 61 REYATAZ r arm 61 irinotecan cisplatin 61 PRADAXA #mg 61 postoperative radiographs 61 percutaneous intervention 61 postprocedure 61 % mlink 61 ACTEMRA TM 61 lowest tertile 61 log# copies mL 61 mmol l 61 recurrent venous thromboembolism 61 graft occlusion 61 myocardial reperfusion 61 rectal tenesmus #.# 61 colon resections 61 intraobserver 61 pneumonectomy 61 lobectomy 61 histologically confirmed 61 noncardiovascular mortality 61 adenoma recurrence 61 abnormal p# biomarker 61 DES implantation 61 multivariable analysis 61 inhospital 61 CR CRu 61 histologic subtype 61 coronary interventions 61 liver histology 61 nonfatal myocardial infarction MI 61 sternotomy 61 refractory ischemia 61 coronary revascularizations 61 paclitaxel eluting stents 61 total abdominal hysterectomy 61 annualized relapse 61 statin monotherapy 61 reoperation 61 nonvertebral fracture 61 ACR# responses 61 Preoperatively 61 Carotid endarterectomy 61 noninferior 61 mg kg dose 61 cardiac perfusion 61 FOLFOX4 61 malperfusion 61 pT2 61 mso header 61 lumen diameter 61 elective PCI 61 univariate analyzes 61 esophagogastroduodenoscopy 61 Noninterest expense totaled 61 noncardiac 61 debulking surgery 61 serum aminotransferase levels 61 clinicopathological features 61 hemodynamically significant 61 sleeve lobectomy 61 endovascular repair 61 crossclamp 61 stomatitis pharyngitis 61 nonobstructive CAD 61 mU liter 61 colorectal adenoma 61 tirofiban 61 clodronate 61 statistical significance p 61 Rating Scale MADRS 61 abdominal hysterectomy 61 Severe acneform rash 61 Available Seat Kilometres ASKs 61 IRLS score 61 comparator arm 61 tipranavir r 61 CTEPH 61 Coronary artery bypass grafting 61 symptomatic aortic stenosis 61 nonoperative treatment 61 % CI #.#-#.# [004] 61 stent thromboses 61 advanced adenomas 61 IFL chemotherapy regimen 61 Montgomery Asberg Depression 61 undergoing radical cystectomy 61 Non GAAP Operating Margin 61 de novo AML 61 5-fluorouracil/leucovorin 60 systolic dysfunction 60 ascending aortic 60 mCi kg 60 foveal thickness 60 ARCALYST ® 60 ARB telmisartan 60 nausea dehydration dyspnea 60 carotid endarterectomy CEA 60 cystectomy 60 CDAI score 60 Am J Cardiol 60 Non inferiority 60 graft dysfunction 60 pericardial effusion 60 evaluable subjects 60 ACR Pedi 60 Papillary 60 VELCADE melphalan 60 atrioventricular block 60 radical cystectomy 60 timepoints 60 lung resections 60 pyrexia mucositis sepsis febrile 60 mL/min/#.# m2 60 μg L 60 axillary node dissection 60 detrusor overactivity 60 Annualized ROE 60 Platelet counts 60 tertile 60 BPH Symptom Score 60 methotrexate monotherapy 60 Breslow thickness 60 proximal DVT 60 Nonaccrual loans totaled 60 atorvastatin #mg 60 Hazard Ratio = 60 CIN3 60 biventricular repair 60 myocardial infarction MI 60 p = ns 60 FOLFIRI alone 60 Soriatane R acitretin capsules 60 chemoembolization 60 intracerebral hemorrhages 60 microbiologically evaluable 60 #Gy 60 endarterectomy 60 Lumbar spine 60 #.#mg/dL 60 mmHg p = 60 ejection fraction EF 60 segmentectomy 60 fullyear outturn represents 60 Montgomery Åsberg Depression 60 perioperative morbidity 60 HDRS 60 vertebral fracture 60 serum creatinine levels 60 pooled comparator 60 thrombocytopenic 60 SVR# 60 Castration Resistant Prostate Cancer 60 intraoperative complications 60 ratio ICER 60 cisplatin vinorelbine 60 ALND 60 onset atrial fibrillation 60 intracranial atherosclerosis 60 fraction LVEF 60 Ebstein anomaly 60 mRS 60 secondary efficacy endpoint 60 anastomotic leak 60 clinically evaluable patients 60 intact parathyroid hormone 60 endosonography 60 intravitreal injections 60 Tumor Response 60 albumin excretion rate 60 mean baseline HbA1c 60 Hazard Ratio HR 60 Charlson comorbidity index 60 aldosterone antagonist 60 multivariate analyzes 60 intravesical therapy 60 Medicare Advantage MLR 60 nonobese 60 target vessel revascularization 60 noninvasive outpatient 60 highest tertile 60 revascularisation 60 incisional 60 esophageal resection 60 Comparable RevPAR 60 sUA 60 multivessel disease 60 Wireline adjusted EBITDA 60 angioplasty stenting 60 multivariable adjusted 60 UPDRS motor 60 Events MACE 60 salpingo oophorectomy 60 intracerebral hemorrhage ICH 60 -#.# mg dL [001] 60 OS = ISD/#/#/# 60 postdischarge 60 Repliform R revenues 60 CYPHER ® 60 mineral density BMD 60 HF hospitalization 60 cytogenetic response 60 hematologic toxicity 60 sustained ventricular tachycardia 60 non splenectomized 60 Acneform rash occurred 60 postinjury 60 FDG uptake 60 aged ≥ 60 oral hypoglycemic agent 60 creatinine ratio 60 mg p = 60 CHD CVD 60 tertiles 60 recanalization 60 elevated ALT 60 Enq# index 60 CIN3 + 60 VcMP 60 acute myocardial infarctions 60 Nonperforming loans totaled 60 CLL SLL 60 odds ratios ORs 60 Doxil ® 60 complete cytogenetic response 60 somatostatin analog 60 8 Cyl 60 endoscopic remission 60 artery stenosis 60 infarct size 60 Nephrol Dial Transplant 60 thromboembolic complications 60 intima media thickness 60 receiving PEGINTRON 60 Adjusted EBITDA1 60 recurrent DVT 60 nonfasting triglyceride levels 60 symptomatic intracranial 60 periprocedural MI 60 ug kg 60 thoracotomy 60 coronary revascularization procedures 60 CIN2 + 60 percutaneous vertebroplasty 60 nonvertebral fractures 59 prioryear 59 Hypotension 59 DLQI 59 segment binary restenosis 59 fractional shortening 59 Active Trader DARTs 59 ischemic cardiomyopathy 59 myocardial infarction ventricular fibrillation 59 creatine kinase MB 59 median sternotomy 59 % CI #.#-#.# [001] 59 radiochemotherapy 59 sternal wound infections 59 margin teb 59 QRS duration 59 OBOP showed 59 Key secondary endpoints 59 atypical ductal hyperplasia 59 remission CR 59 adrenalectomy 59 IBDQ 59 weekly CSBMs 59 nephrectomy 59 titrated glipizide 59 p = #.# [003] 59 receiving INTRON 59 #mg dosing group 59 Projections ranged 59 glycated hemoglobin HbA1c 59 OCF margin 59 achieving PASI 59 p = .# [002] 59 hemiarthroplasty 59 Billable headcount 59 transfemoral 59 Transcatheter aortic valve implantation 59 psychiatric comorbidity 59 adefovir treated 59 CYPHER ® Stent 59 hsCRP levels 59 Churn Rate 59 undergoing CABG 59 hours postdose 59 ECOG PS 59 artery bypass 59 Scale EDSS 59 TEVAR 59 MitraClip device 59 MIRP 59 Consensus +#.# 59 myocardial viability 59 heFH 59 placebo PBO 59 myocardial infarction stroke 59 corticosteroid dose 59 postoperative complications 59 empyema 59 ximelagatran 59 serum estradiol 59 low dose cytarabine 59 cytoreductive surgery 59 Nasdaq Composite COMP #.# 59 carotid artery stenting CAS 59 hepatocellular carcinomas 59 Zometa hazard 59 univariate analysis 59 workhorse lesions 59 FHLB advances decreased 59 pelvic lymphadenectomy 59 postoperative infection 59 locoregional control 59 pmol L 59 VATS lobectomy 59 onset diabetes mellitus 59 TAXUS Stent 59 Munghana Lonene Listenership 59 achieved sustained virological 59 DAS# scores 59 resected pancreatic cancer 59 receiving golimumab 59 ACR# response 59 biliary tract cancer 59 stent binary restenosis 59 ® fluocinonide Cream 59 Left Ventricular Ejection Fraction 59 median PFS 59 octreotide LAR 59 receiving ISENTRESS 59 metoprolol tartrate 59 seminal vesicle invasion 59 Noninterest expense decreased 59 P ≤ 59 μg liter 59 haematologic 59 bilateral oophorectomy 59 resectable pancreatic cancer 59 noninterest expense decreased 59 COPD exacerbation 59 mcg BID 59 Partial Responses 59 inotropic therapy 59 Pharmacokinetic parameters 59 EBRT 59 R# #mg BID 59 metformin monotherapy 59 nonfatal stroke 59 progression TTP 59 CABG 59 full thickness plication 59 HealthGrades analyzed 59 quetiapine risperidone 59 peripheral sensory neuropathy 59 Cardiac Surgery Systems 59 -#.# log# copies mL 59 uncoated stent 59 adnexal mass 59 Interest Expense Interest expense 59 blastic phase 59 CIMZIA TM certolizumab pegol 59 lumbar disk herniation 59 Ann Intern Med 59 curative resection 59 Median progression 59 baseline A1C 59 sd = 59 Serious adverse reactions 59 HSCT 59 Acute Coronary Syndromes ACS 59 specific alkaline phosphatase 59 specific antigen PSA 59 leukocyte count 59 tumor resection 59 chemoradiotherapy 59 adjuvant radiotherapy 59 tenecteplase 59 atrioventricular valve 59 CRp 59 eplerenone 59 SCr 59 statistically significant p = 59 hypoperfusion 59 elevated serum creatinine 59 NHANES III 59 Postoperatively 59 x ULN 59 completely resected 59 STRIDE PD 59 nmol liter 59 gauge vitrectomy 59 stenoses 59 preoperatively 59 parous women 59 seroprotection 59 adenoidectomy 59 Medcath NASDAQ MDTH 59 pmol liter 59 bortezomib refractory 59 FFR guided 59 log# IU mL 59 intracranial hemorrhage ICH 59 chlorambucil 59 intraventricular hemorrhage 59 HbA 1c 59 % AST SGOT 59 recurrent glioblastoma multiforme 59 WOMAC scores 59 composite endpoint 59 neurodevelopmental impairment 59 International Liftboats 59 Oncophage vaccination 59 -#.# mg dL [002] 59 invasive carcinomas 59 locoregional disease 59 severe mitral regurgitation 59 calculated creatinine clearance 59 TOTAL REV 59 was#.# 59 RECORD1 59 EXJADE 59 Blended ARPU 59 Wireline EBITDA 59 AVAILABLE SEAT KM 59 recurrent GBM 59 wound dehiscence 59 pulmonary artery banding 59 cGy 59 serum phosphorous 59 XELOX 59 serologically active patients 59 pamidronate 59 renal cell carcinomas 59 interstitial brachytherapy 59 luminal diameter 59 4mg/kg 59 Hb A1c 59 quarter offiscal 59 â ‰ ¥ 59 neoadjuvant radiation 59 KRAS wild 59 receiving XGEVA 59 multivariable analyzes 59 neutropenia dehydration dyspnea 59 adenotonsillectomy 59 drug eluting stent implantation 59 plus methotrexate 59 IM progesterone 59 confidence interval CI 59 atherosclerotic renal artery stenosis 59 pretest probability 58 salmeterol fluticasone 58 Adjuvant chemotherapy 58 obstructive CAD 58 total hip arthroplasties 58 Scale EDSS score 58 parenchymal 58 bi ventricular pacing 58 pg ml 58 thyrotropin levels 58 ADCS CGIC 58 tumor progression TTP 58 DJI #.# 58 CSDs Dr Pepper 58 lumbar spine bone 58 Patency 58 lymphocyte count 58 Hycamtin ® 58 polypoid 58 T2 lesion volume 58 nonelective 58 RE LY ® 58 thyroidectomy 58 fibrinolysis 58 dose atorvastatin 58 microg 58 GG genotype 58 Eric Medlen Mustang 58 NATRECOR R 58 carotid revascularization 58 mineral density 58 mg/m2 dose 58 subscore 58 hypophosphatemia 58 cytoreductive nephrectomy 58 follicular lymphomas 58 VT VF 58 tricuspid regurgitation 58 malignant neoplasms 58 splenectomized 58 linaclotide treated 58 metastatic carcinoid tumors 58 video assisted thoracoscopic 58 X ULN 58 TIMP 1 58 plasma cortisol 58 Renal Cell Carcinoma RCC 58 revision arthroplasty 58 CsA 58 venous thromboembolic disease 58 diabetes mellitus DM 58 Tumor shrinkage 58 baseline Hb 58 extracranial 58 neurologic impairment 58 cerebral angiography 58 underwent percutaneous coronary 58 normothermic 58 mg hydrochlorothiazide 58 response pCR 58 concomitant AEDs 58 BRCA1 mutation carriers 58 perioperatively 58 hypokalemia 58 antegrade 58 symptomatic intracerebral hemorrhage 58 Myocardial infarction 58 HbA1c levels 58 J Antimicrob Chemother 58 ng dL 58 sirolimus eluting 58 imipenem 58 Partial Response 58 glycosylated hemoglobin HbA1c 58 divalproex sodium 58 care regimens CCR 58 allogeneic HSCT 58 anemia hemoglobin 58 RLEC adjusted EBITDA 58 Preprint revenues 58 chronic periodontitis 58 mcg linaclotide 58 Viread Emtriva SUSTIVA 58 μmol L 58 moderately emetogenic 58 alteplase 58 logMAR 58 treated nonsurgically 58 tibial shaft 58 β blockers 58 XIENCE V stent 58 extracolonic findings 58 Unified Parkinson Disease 58 RECIST Response Evaluation Criteria 58 carotid artery stenosis 58 Noninterest Expense Noninterest expense 58 ELBW infants 58 FDA defined valvulopathy 58 arteriography 58 carotid endarterectomy 58 conventional coronary angiography 58 scleral buckling 58 metastatic GIST 58 nonfasting triglycerides 58 transurethral 58 receiving prophylactic anticoagulation 58 reintubation 58 poor metabolizers 58 reduce serum phosphate 58 Coronary Artery Bypass Grafting 58 dose Iluvien 58 postop 58 X ray angiography 58 AUA Symptom Score 58 androgen suppression 58 coronary revascularisation 58 thromboses 58 skeletal metastases 58 recurrent ischemia 58 axillary node 58 g dl 58 dose pravastatin 58 cytoreduction 58 pulmonary capillary wedge 58 aortic insufficiency 58 multivariate Cox 58 FOLFOX4 alone 58 invasive angiography 58 Sees FY# revs 58 doxorubicin cyclophosphamide 58 MARRIOTT REVENUES totaled 58 iniparib BSI 58 Sustained virologic response 58 Ann Oncol 58 histologically 58 nicardipine 58 Gastrointestinal Stromal Tumors 58 prostate TURP 58 oral levofloxacin 58 Thrombolysis 58 NSTE ACS 58 osteoid 58 estimated glomerular filtration 58 achieved PASI 58 colorectal metastases 58 kidney allograft 58 Secondary endpoints included 58 rFSH 58 concurrent chemoradiation 58 locoregional 58 receiving highly emetogenic 58 mm Hg diastolic 58 β blocker 58 residual stenosis 58 interquartile range IQR 58 hip arthroplasty 58 A1c levels 58 serum HBV DNA 58 Angiomax monotherapy 58 6 Cyl 58 sustained virological response 58 SELENA SLEDAI score 58 plain radiographs 58 Gross Profit Percentage 58 MVAS gross 58 coronary stenoses 58 unicompartmental knee arthroplasty 58 Adjustment Expenses 58 liver metastasis 58 fibrinolytic therapy 58 postoperative atrial fibrillation 58 posttransplant 58 diagnostic angiography 58 Skin sterol 58 leiomyomas 58 Subgroup analysis 58 ug dose 58 conventional angiography 58 partial nephrectomy 58 dose dabigatran 58 Additive Technologies 58 SOXX gained 58 TLUS 58 anthracycline taxane 58 dosing cohort 58 total hip arthroplasty 58 maximal treadmill 58 Jeg Coughlin Cobalt 58 aminotransferase elevations greater 58 renal artery stenosis 58 hepatic metastases 58 trabeculectomy 58 OPANA franchise 58 Response Evaluation Criteria 58 mg Proellex 58 retrospective observational study 58 percutaneous transluminal coronary angioplasty 58 preoperative intraoperative 58 T1c 58 #mmHg [001] 58 Arterial stiffness 58 intravascular ultrasonography 58 FTE staffing 58 Cystatin C 58 FOLFOX6 58 mg XP# 58 atherogenic dyslipidemia 58 ER CHOP 58 variceal 58 PCIs 58 myocardial necrosis 58 symptomatic hyponatremia 58 hippocampal atrophy 58 Leasable area 58 clinically localized prostate 58 revascularization 58 carotid artery blockage 58 Refinery utilization rebounded 58 ICD therapy 58 comorbidity 58 baseline serum bilirubin 58 cerebrovascular accident 58 Myocardial Infarction Study 58 hepatic insulin sensitivity 58 endometrial thickness 58 nondepressed 58 esophageal carcinoma